6P5M
Discovery of a Novel, Highly Potent, and Selective Thieno[3,2-d]pyrimidinone-Based Cdc7 inhibitor with a Quinuclidine Moiety (TAK-931) as an Orally Active Investigational Anti-Tumor Agent
Summary for 6P5M
| Entry DOI | 10.2210/pdb6p5m/pdb |
| Descriptor | Rho-associated protein kinase 2, 6-(5-methyl-1H-pyrazol-4-yl)-2-[(pyrrolidin-1-yl)methyl]thieno[3,2-d]pyrimidin-4(3H)-one (3 entities in total) |
| Functional Keywords | kinase, inhibitor, oral, anti-tumor, transferase-transferase inhibitor, transferase-transferase inhibitor complex, transferase/transferase inhibitor |
| Biological source | Homo sapiens (Human) |
| Total number of polymer chains | 4 |
| Total formula weight | 185500.72 |
| Authors | Hoffman, I.D.,Skene, R.J. (deposition date: 2019-05-30, release date: 2020-01-15, Last modification date: 2023-10-11) |
| Primary citation | Kurasawa, O.,Miyazaki, T.,Homma, M.,Oguro, Y.,Imada, T.,Uchiyama, N.,Iwai, K.,Yamamoto, Y.,Ohori, M.,Hara, H.,Sugimoto, H.,Iwata, K.,Skene, R.,Hoffman, I.,Ohashi, A.,Nomura, T.,Cho, N. Discovery of a Novel, Highly Potent, and Selective Thieno[3,2-d]pyrimidinone-Based Cdc7 Inhibitor with a Quinuclidine Moiety (TAK-931) as an Orally Active Investigational Antitumor Agent. J.Med.Chem., 63:1084-1104, 2020 Cited by PubMed: 31895562DOI: 10.1021/acs.jmedchem.9b01427 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.65 Å) |
Structure validation
Download full validation report
